Thrivent Financial for Lutherans
CTMX icon

Thrivent Financial for Lutherans’s CytomX Therapeutics CTMX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,175
Closed -$83K – 2475
2021
Q2 		$83K Sell
13,175
-20,670
-61% -$161K ﹤0.01% 2438
2021
Q1 		$262K Sell
33,845
-56,757
-63% -$449K ﹤0.01% 2417
2020
Q4 		$593K Hold
90,602
– – ﹤0.01% 2057
2020
Q3 		$602K Buy
90,602
+41,078
+83% +$305K ﹤0.01% 1871
2020
Q2 		$412K Hold
49,524
– – ﹤0.01% 1989
2020
Q1 		$380K Buy
+49,524
New +$345K ﹤0.01% 1868

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Thrivent Financial for Lutherans's CTMX Position: Q3 2021 in Review

Thrivent Financial for Lutherans sold out of CytomX Therapeutics (CTMX) in Q3 2021, closing a stake of 13,175 shares — an estimated $83K sold.

Thrivent Financial for Lutherans first reported a position in CTMX in Q1 2020 and held it in 6 quarters. The position peaked at $602K in Q3 2020. 114 funds tracked by Wall St. Rank hold CTMX as of Q3 2021.

  • Thrivent Financial for Lutherans reported no remaining CytomX Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 13,175 CytomX Therapeutics shares in Q3 2021, an estimated $83K.
  • Thrivent Financial for Lutherans first reported a position in CytomX Therapeutics in Q1 2020 and held it in 6 quarters.
  • Thrivent Financial for Lutherans's CytomX Therapeutics position peaked at $602K in Q3 2020.
  • 114 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2021.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2021, filed 15 Nov 2021.